Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications

Experimental Biology and Medicine

Volumn 241, Issue 12, 2016, Pages 1323-1331

  Brannick, Ben ^a   Wynn, Anne ^a   Dagogo Jack, Samuel ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Impaired fasting glucose; impaired glucose tolerance; macrovascular; microvascular; prediabetes complications; prevention

Indexed keywords

ACARBOSE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HEXOSAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; POLYOL; PROTEIN KINASE C; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BODY MASS; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DIET; DISEASE COURSE; EXERCISE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIPOLYSIS; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; RISK FACTOR; WAIST CIRCUMFERENCE; ANIMAL; COMPLICATION; DIABETIC ANGIOPATHY; DISEASE MODEL; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; HUMANS; PREDIABETIC STATE;

EID: 84975062045     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370216654227     Document Type: Article

References (81)

1. World Health Organization. Global status report on noncommunicable diseases 2014, Geneva, Switzerland: WHO Press, 2014.
2. F.Hu. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care2011; 34: 1249–57.
3. E.D’AdamoS.Caprio. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care2011; 34: S161–5.
4. K.M.BullardS.H.SaydahG.ImperatoreC.C.CowieE.W.GreggL.S.GeissY.J.ChengD.B.RolkaD.E.WilliamsC.J.Caspersen. Secular changes in the U.S. prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examinations Surveys, 1999–2010. Diabetes Care2013; 36: 2286–93.
5. C.C.CowieK.F.RustE.S.FordM.S.EberhardtD.D.Byrd-HoltC.LiD.E.WilliamsE.W.GreggK.E.BainbridgeS.H.SaydayL.S.Geiss. Full accounting of diabetes and prediabetes in the US population 1988–1994 and 2005–2006. Diabetes Care2009; 32: 287–94.
6. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014, Atlanta, GA: US Department of Health and Human Services, 2014.
7. R.A.HaywardP.D.ReavenW.L.WiitalaG.D.BahnD.J.RedaL.GeM.McCarrenW.C.DuckworthM.V.Emanuele. VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med2015; 372: 2197–206.
8. P.GaedeH.Lund-AndersenH.H.ParvingO.Pedersen. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580–91.
9. J.B.Echouffo-TcheuguiS.Dagogo-Jack. Preventing diabetes mellitus in developing countries. Nat Rev Endocrinol2012; 8: 557–62.
10. S.Dagogo-Jack. Primary prevention of cardiovascular disease in prediabetes: the glass is half-full and half-empty. Diabetes Care2005; 28: 971–2.
11. N.Bansal. Prediabetes diagnosis and treatment: a review. World J Diabetes2015; 6: 296–303.
12. L.MaschirowK.KhalafH.A.Al-AubaidyH.F.Jelinek. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes – biomarkers as a possible tool for early disease detection for rural screening. Clin Biochem2015; 48: 581–5.
13. A.BaharA.MakhloughA.YousefiZ.KashiS.Abediankenari. Correlation between prediabetes conditions and microalbuminuria. Nephrourol Mon2013; 5: 741–4.
14. American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care2016; 39: S1–112.
15. International Diabetes Federation. IDF diabetes atlas, 7th ed. Brussels, Belgium: International Diabetes Federation, 2015.
16. S.GenuthK.G.AlbertiP.BennettJ.BuseR.DeFronzoR.KahnJ.KitzmillerW.C.KnowlerH.LebovitzA.LernmarkD.NathanJ.PalmerR.RizzaC.SaudekJ.ShawM.SteffesM.SternJ.TuomilehtoP.Zimmet. The expert committee on the diagnosis and classification of Diabetes Mellitus: 2003 follow-up report on the diagnosis of diabetes mellitus. Diabetes Care2003; 26: 3160–67.
17. M.ShimodairaS.OkaniwaN.HanyuT.Nakayama. Optimal hemoglobin A1c levels for screening of diabetes and prediabetes in the Japanese population. J Diabetes Res2015; 2015: 932057–932057.
18. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation, Geneva: World Health Organization, 2006, pp. 1–50.
19. S.LiJ.XiaoL.JiJ.WengW.JiaJ.LuZ.ZhouX.GuoJ.LiuZ.ShanD.ZhuL.ChenZ.ZhaoH.TianQ.JiJ.GeQ.LiL.LinZ.YangJ.HeW.Yang. China National Diabetes and Metabolic Disorders Study Investigators. BMI and waist circumference are associated with impaired glucose metabolism and type 2 diabetes in normal weight Chinese adults. J Diabetes Complications2014; 28: 470–6.
20. W.C.KnowlerE.Barrett-ConnorS.E.FowlerR.F.HammanJ.M.LachinE.A.WalkerD.M.Nathan. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346: 393–403.
21. E.A.NyenweS.Dagogo-Jack. Metabolic syndrome, prediabetes and the science of primary prevention. Minerva Endocrinol2011; 36: 129–45.
22. M.KanatR.DeFronzoM.Abdul-Ghani. Treatment of prediabetes. World J Diabetes2015; 6: 1207–22.
23. S.Dagogo-JackH.AskariG.Tykodi. Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab2009; 94: 2031–6.
24. S.Dagogo-JackC.EdeogaS.EbeniboE.NyenweJ.Wan. Lack of racial disparity in incident prediabetes and glycemic progression among black and white offspring of parents with type 2 diabetes: the pathobiology of prediabetes in a biracial cohort (POP-ABC) study. J Clin Endocrinol Metab2014; 99: E1078–87.
25. C.WeyerP.A.TataranniC.BogardusR.E.Pratley. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care2001; 24: 89–94.
26. M.BajajR.DeFronzo. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol2003; 10: 311–23.
27. M.Abdul-GhaniR.DeFronzo. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol2010; 2010: 476279–476279.
28. M.KanatD.WinnierL.NortonN.ArarC.JenkinsonR.A.DeFronzoM.A.Abdul-Ghani. The relationship between β-cell function and glycated hemoglobin: results from the Veterans Administration Genetic Epidemiology Study. Diabetes Care2011; 34: 1006–10.
29. G.WeirS.Bonner-Weir. Five stages of evolving progression to diabetes. Diabetes2004; 53: S16–21.
30. M.KanatA.MariL.NortonD.WinnierR.A.DeFronzoC.JenkinsonM.A.Abdul-Ghani. Distinct β-Cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes2012; 61: 447–53.
31. C.WeyerC.BogardusD.M.MottR.Pratley. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest1999; 104: 787–94.
32. A.E.KitabchiM.TemprosaW.C.KnowlerS.E.KahnS.E.FowlerS.M.HaffnerR.AndresC.SaudekS.L.EdelsteinR.ArakakiM.B.MurphyH.Shamoon. Diabetes Prevention Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes2005; 54: 2404–14.
33. M.A.NauckI.VardarliC.F.DeaconJ.J.HolstJ.J.Meier. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?Diabetologia2011; 54: 10–18.
34. M.B.Toft-NielsenM.B.DamholtS.MadsbadL.M.HilstedT.E.HughesB.K.MichelsenJ.J.Holst. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab2001; 86: 3717–23.
35. G.Papaetis. Incretin-based therapies in prediabetes: current evidence and future perspectives. World J Diabetes2014; 5: 817–34.
36. A.LopategiC.López-VicarioJ.Alcaraz-QuilesV.García-AlonsoB.RiusE.TitosJ.Clària. Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. Mol Cell Endocrinol2016; 419: 44–59.
37. E.CerasiR.Luft. The prediabetic state, its nature and consequences – a look toward the future. Diabetes1972; 21(Suppl 2): 685–94.
38. G.Boden. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes1997; 46: 3–10.
39. A.A.BoucherC.EdeogaS.EbeniboJ.WanS.Dagogo-Jack. Leukocyte count and cardiometabolic risk among healthy subjects with parental type 2 diabetes: the Pathobiology of Prediabetes in a Biracial Cohort Study. Ethn Dis2012; 22: 445–50.
40. S.G.AndersonW.B.DunnM.BanerjeeM.BrownD.I.BroadhurstR.GoodacreG.J.CooperD.B.KellJ.K.Cruicshank. Evidence that multiple defects in lipid regulation occur before hyperglycemia during the prodrome of type-2 diabetes. PLoS One2014; 9: e103217–e103217.
41. C.SabanayagamA.ShankarS.C.LimJ.LeeE.S.TaiT.Y.Wong. Serum C-reactive protein level and prediabetes in two Asian populations. Diabetologia2011; 54: 767–75.
42. N.C.OlsonP.W.CallasA.J.HanleyA.FestaS.M.HaffnerL.E.WagenknechtR.P.Tracy. Circulating levels of TNF-α are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab2012; 97: 1032–40.
43. K.J.MatherT.FunahashiY.MatsuzawaS.EdelsteinG.A.BrayS.E.KahnJ.CrandallS.MarcovinaB.GoldsteinR.Goldberg. Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes2008; 57: 980–6.
44. R.BasuC.BarosaJ.JonesS.DubeR.CarterA.BasuR.A.Rizza. Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia. J Clin Endocrinol Metab2013; 98: E409–17.
45. L.PerreaultB.C.BergmanM.C.PlaydonC.Dalla ManC.CobelliR.H.Eckel. Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes?Am J Physiol Endocrinol Metab2008; 295: E428–35.
46. E.SelvinM.LazoY.ChenL.ShenJ.RubinJ.W.McEvoyR.C.HoogeveenA.R.SharrettC.M.BallantyneJ.Coresh. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation2014; 130: 1374–82.
47. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004 21;14:413–420
48. B.BalkauE.EschwègeL.PapozJ.L.RichardJ.R.ClaudeJ.M.WarnetP.Ducimetière. Risk factors for early death in non-insulin dependent diabetes in men with known glucose tolerance status. BMJ1993; 307: 295–9.
49. S.Dagogo-JackN.EgbuonuC.Edeoga. Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. Med Princ Pract2010; 19: 167–75.
50. S.Dagogo-JackEndocrinology & metabolism: complications of diabetes mellitus. In: (eds). Scientific American medicine, Hamilton, ON: Decker Intellectual Properties, 2015.
51. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med2007; 24: 137–44.
52. S.FonvilleA.A.ZandbergenP.J.KoudstaalH.M.den Hertog. Prediabetes in patients with stroke or transient ischemic attack: prevalence, risk and clinical management. Cerebrovasc Dis2014; 37: 393–400.
53. J.LamparterP.RaumN.PfeifferA.MirshahiR.HöhnH.ElfleinT.PetoP.WildA.SchulzA.Schneider. Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study. J Diabetes Complications2014; 28: 482–7.
54. M.LottJ.SlocombV.ShivkumarB.SmithD.QuillenR.GabbayT.W.GardnerK.Bettermann. Impaired retinal vasodilator responses in prediabetes and type 2 diabetes. Acta Ophthalmol2013; 91: e462–9.
55. N.PapanasA.I.VinikD.Ziegler. Neuropathy in prediabetes: does the clock start ticking early?Nat Rev Endocrinol2011; 7: 682–90.
56. K.YlitaloW.HermanS.Harlow. Monofilament insensitivity and small and large nerve fiber symptoms in impaired fasting glucose. Prim Care Diabetes2013; 7: 309–13.
57. M.Brownlee. Banting lecture 2004: the pathobiology of diabetic complications – a unifying mechanism. Diabetes2005; 54: 1615–25.
58. S.RahmanT.RahmanA.A.IsmailA.R.Rashid. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab2007; 9: 767–80.
59. H.KawanoT.MotoyamaO.HirashimaN.HiraiY.MiyaoT.SakamotoK.KugiyamaH.OgawaH.Yasue. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol1999; 34: 146–54.
60. S.Dagogo-Jack. Metabolomic prediction of diabetes and cardiovascular risk. Med Princ Pract2012; 21: 401–3.
61. T.J.WangM.G.LarsonR.S.VasanS.ChengE.P.RheeE.McCabeG.D.LewisC.S.FoxP.F.JacquesC.FernandezC.J.O'DonnellS.A.CarrV.K.MoothaJ.C.FlorezA.SouzaO.MelanderC.B.ClishR.E.Gerszten. Metabolite profiles and the risk of developing diabetes. Nat Med2011; 17: 448–53.
62. N.D.PalmerR.D.StevensP.A.AntinozziA.AndersonR.N.BergmanL.E.WagenknechtC.B.NewgardD.W.Bowden. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab2015; 100: E463–8.
63. J.TuomilehtoJ.LindströmJ.G.ErikssonT.T.ValleH.HämäläinenP.Ilanne-ParikkaS.Keinänen-KiukaanniemiM.LaaksoA.LouherantaM.RastasV.SalminenM.Uusitupa. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001; 344: 1343–50.
64. X.R.PanG.W.LiY.H.HuJ.X.WangW.Y.YangZ.X.AnZ.X.HuJ.LinJ.Z.XiaoH.B.CaoP.A.LiuX.G.JiangY.Y.JiangJ.P.WangH.ZhengH.ZhangP.H.BennettB.V.Howard. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care1997; 20: 537–44.
65. G.LiP.ZhangJ.WangY.AnQ.GongE.W.GreggW.YangB.ZhangY.ShuaiJ.HongM.M.EngelgauH.LiG.RoglicY.HuP.H.Bennett. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol2014; 2: 474–80.
66. A.RamachandranC.SnehalathaA.YamunaS.MaryZ.Ping. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007; 30: 2548–52.
67. A.TabákC.HerderW.RathmannE.BrunnerM.Kivimäki. Prediabetes: a high-risk state for diabetes development. Lancet2012; 379: 2279–90.
68. U.HostalekM.GwiltS.Hildemann. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs2015; 75: 1071–94.
69. R.A.DeFronzoD.TripathyD.C.SchwenkeM.BanerjiG.A.BrayT.A.BuchananS.C.ClementR.R.HenryH.N.HodisA.E.KitabchiJ.W.MackS.MudalierR.E.RatnerK.WilliamsF.B.StentzN.MusiP.D.Reaven. ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med2011; 364: 1104–15.
70. O.R.PourS.Dagogo-Jack. Prediabetes as a therapeutic target. Clin Chem2011; 57: 215–20.
71. The Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care2003; 26: 977–80.
72. S.Dagogo-JackC.Edeoga. Understanding and identifying pre-diabetes – can we halt the diabetes epidemic?Eur Endocrinol2008; 4: 16–8.
73. H.C.GersteinS.YusufJ.BoschJ.PogueP.SheridanN.DinccagM.HanefeldB.HoogwerfM.LaaksoV.MohanJ.ShawB.ZinmanR.R.Holman. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet2006; 368: 1096–105.
74. G.DanieleR.DeFronzoM.Abdul-Ghani. What are the pharmacotherapy options for treating prediabetes?Expert Opin Pharmacother2014; 15: 2003–18.
75. Y.LiuA.CotillardK.ClementS.W.RizkallaC.VatierO.AllatifJ.P.BastardS.FellahiM.StevantS.BieuveletC.LangloisA.BrochotA.Guilbot. A dietary supplement containing cinnamon, chromium and carnosine decreases fasting plasma glucose and increases lean mass in overweight or obese pre-diabetic subjects: a randomized, placebo-controlled trial. PLoS One2015; 10: e0138646–e0138646.
76. J.L.ChiassonR.G.JosseR.GomisM.HanefeldA.KarasikM.Laakso. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet2002; 359: 2072–7.
77. J.S.TorgersonJ.HauptmanM.N.BoldrinL.Sjöström. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care2004; 27: 155–61.
78. A.RamachandranC.SnehalathaS.MaryB.MukeshA.D.BhaskarV.Vijay. Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia2006; 49: 289–97.
79. A.RamachandranC.SnehalathaS.MaryS.SelvamC.K.KumarA.C.SeeliA.S.Shetty. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia2009; 52: 1019–26.
80. B.ZinmanS.B.HarrisJ.NeumanH.C.GersteinR.R.RetnakaranJ.RaboudY.QiA.J.Hanley. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet2010; 376: 103–11.
81. L.PerreaultM.TemprosaK.J.MatherE.HortonA.KitabchiM.LarkinM.G.MontezD.ThayerT.J.OrchardR.F.HammanR.B.Goldberg. Diabetes Prevention Program Research Group. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program Outcomes Study. Diabetes Care2014; 37: 2622–31.